TY - GEN
T1 - Thymosin β4
T2 - A key factor for protective effects of eEPCs in acute and chronic ischemia
AU - Hinkel, Rabea
AU - Bock-Marquette, Ildiko
AU - Hazopoulos, Antonis K.
AU - Kupatt, Christian
PY - 2010/4
Y1 - 2010/4
N2 - Acute myocardial infarction is still one of the leading causes of death in the industrial nations. Even after successful revascularization, myocardial ischemia results in a loss of cardiomyocytes and scar formation. Embryonic EPCs (eEPCs), retroinfused into the ischemic region of the pig heart, provided rapid paracrine benefit to acute and chronic ischemia in a PI-3K/Akt-dependent manner. In a model of acute myocardial ischemia, infarct size and loss of regional myocardial function decreased after eEPC application, unless cell pre-treatment with thymosin β4 shRNA was performed. Thymosin ß4 peptide retroinfusion mimicked the eEPC-derived improvement of infarct size and myocardial function. In chronic ischemia (rabbit model), eEPCs retroinfused into the ischemic hindlimb enhanced capillary density, collateral growth, and perfusion. Therapeutic neovascularization was absent when thymosin ß4 shRNA was introduced into eEPCs before application. In conclusion, eEPCs are capable of acute and chronic ischemia protection in a thymosin ß4 dependent manner.
AB - Acute myocardial infarction is still one of the leading causes of death in the industrial nations. Even after successful revascularization, myocardial ischemia results in a loss of cardiomyocytes and scar formation. Embryonic EPCs (eEPCs), retroinfused into the ischemic region of the pig heart, provided rapid paracrine benefit to acute and chronic ischemia in a PI-3K/Akt-dependent manner. In a model of acute myocardial ischemia, infarct size and loss of regional myocardial function decreased after eEPC application, unless cell pre-treatment with thymosin β4 shRNA was performed. Thymosin ß4 peptide retroinfusion mimicked the eEPC-derived improvement of infarct size and myocardial function. In chronic ischemia (rabbit model), eEPCs retroinfused into the ischemic hindlimb enhanced capillary density, collateral growth, and perfusion. Therapeutic neovascularization was absent when thymosin ß4 shRNA was introduced into eEPCs before application. In conclusion, eEPCs are capable of acute and chronic ischemia protection in a thymosin ß4 dependent manner.
KW - Angiogenesis
KW - Infarct size
KW - Ischemia/reperfusion
KW - Progenitor cells
KW - Thymosin β4
UR - http://www.scopus.com/inward/record.url?scp=77951778555&partnerID=8YFLogxK
U2 - 10.1111/j.1749-6632.2010.05489.x
DO - 10.1111/j.1749-6632.2010.05489.x
M3 - Conference contribution
C2 - 20536456
AN - SCOPUS:77951778555
SN - 9781573318013
T3 - Annals of the New York Academy of Sciences
SP - 105
EP - 111
BT - Thymosins in Health and Disease
PB - Blackwell Publishing Inc.
ER -